Understanding GOLD Updates and Role of Emerging Biologics in COPD Management

This activity is part 2 of a 3-part webinar curriculum and includes a Powered by Patients™ video interview.

Program Description

Treatment goals for patients with chronic obstructive pulmonary disease (COPD) include relieving underlying chronic lung inflammation and symptoms contributing to disease exacerbations. The current standard of care for pharmacotherapies in COPD management includes inhaled bronchodilators and corticosteroids, as necessary, or orally administered medications. Building upon interest in type 2 inflammatory disease pathophysiology, several biologic drugs are also under investigation for the treatment of COPD. This second webinar in the COPD curriculum will review the most recent updates from the Global Initiative for Chronic Obstructive Lung Disease guidelines for current standards of care as well as the potential role of emerging biologics in COPD management. Efficacy and safety data for emerging biologics for COPD management from recent clinical trials will be presented. Participants will gain perspectives on the challenges in current treatment protocols and how they may affect patient outcomes.

Target audience: Health-system, retail, and specialty pharmacists

Type of activity: Application
Release date: July 26, 2024
Expiration date: July 26, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore updates to the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines on chronic obstructive pulmonary disease (COPD) and its management
• Identify the current standard of care therapies, including limitations and unmet needs, used in the management of COPD
• Analyze emerging biologics for the management of COPD based on efficacy and safety data in clinical trials

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-232-H01-P. The activity is available for CE credit through July 26, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Rupal Mansukhani, PharmD, CTTS, FAPhA

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms